Source link : https://www.newshealth.biz/health-news/itp-drug-disappoints-in-hospitalized-covid-patients-with-hypoxemia/

The spleen tyrosine kinase inhibitor fostamatinib (Tavalisse) did not improve outcomes in adults hospitalized with COVID-19 and hypoxemia, a phase III randomized trial showed. Among 400 patients, the mean number of oxygen-free days was 13.4 for patients in the fostamatinib group and 14.2 for those in the placebo group (adjusted OR 0.82, 95% credible interval […]

Author : News Health

Publish date : 2024-12-04 16:00:38

Copyright for syndicated content belongs to the linked Source.